GE Healthcare has received Food and Drug Administration 510(k) approval of new diagnostic imaging technology for breast care.

The SenoBright Contrast Enhanced Spectral Mammography technology uses a dye with iodine and a "dual energy acquisition technique" to provide contrast-enhanced images of the breast. SenoBright uses X-rays at multiple energies to create two separate but almost simultaneous exposures, according to the Waukesha, Wis.-based vendor.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access